Publication

Video

Supplements and Featured Publications

Targeted Advances in ALK+ NSCLC
Volume1
Issue 1

Dr. Stinchcombe on Remaining Challenges in ALK+ NSCLC

Thomas E. Stinchcombe, MD, discusses remaining challenges in ALK-positive non­–small cell lung cancer.

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses remaining challenges in ALK-positive non­—small cell lung cancer (NSCLC).

Though patients are responding well to upfront next-generation TKIs, the optimal treatment strategy for patients who experience disease progression is unclear, says Stinchcombe.

Chemotherapy or single-agent lorlatinib (Lorbrena) are potential regimens with response rates around 40% to 45% and a progression-free survival benefit of 6 to 8 months, explains Stinchcombe. Importantly, lorlatinib has a high rate of central nervous system activity that may benefit patients with brain metastases.

Remaining questions regarding repeat tumor biopsy, the utility of circulating tumor DNA, and how to further personalize treatment for patients need to be explored further, highlights Stinchcombe.

Additionally, up to 50% of patients will not have an ALK mutation either because insensitive testing did not catch a mutation, or because the patient has ALK-independent mechanisms of resistance. Understanding the optimal treatment for these patients is critical going forward, Stinchcombe concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity